The effect of Ramipril and Telmisartan on blood pressure and insulin resistance in hypertensive patients

Vaibhav Watts; Bhupinder Singh; Jaswant Rai

doi:10.18203/2319-2003.ijbcp20192186

Authors

Vaibhav Watts Department of Pharmacology, Government Medical College, Amritsar, Punjab, India
Bhupinder Singh Government Medical College, Amritsar, Punjab, India
Jaswant Rai Department of Pharmacology, Government Medical College, Amritsar, Punjab, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20192186

Keywords:

HOMA-IR, Hypertension, Ramipril, Telmisartan

Abstract

Background: Angiotensin converting enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs) have become keystones of therapy for hypertension but there are very few studies where they have been compared with each other. This study attempted to compare the effect of Ramipril and Telmisartan on Blood Pressure and Insulin Resistance in Hypertensive patients (JNC 8).

Methods: An open label, randomized, prospective and comparative study of twelve- week duration was conducted on 60 patients of hypertension (JNC-8), with the collaboration of Department of Pharmacology and Department of Medicine, Government Medical College, Amritsar. Group A and B were given Telmisartan 40mg and Ramipril 2.5 mg OD respectively. Blood Pressure was recorded on every visit, whereas, fasting plasma insulin and HOMA-IR values were recorded at the baseline and at the end of the study. Fasting blood sugar was done at 0, 4 and 12 weeks.

Results: At the end of 12 weeks, a significant reduction in Systolic/Diastolic blood pressure was observed in group A with a drop of ~14/9 mmHg (p<0.001) and in group B too, the fall of ~11.6/7.2 mmHg was significant (p<0.001). However, in inter-group comparison only SBP difference was significant between two groups (p<0.05). Change in HOMA-IR value was also significant in both the groups (p<0.001). The inter-group difference for HOMA-IR between both the groups (A vs B) was also statistically significant (p<0.01).

Conclusions: Telmisartan 40 mg OD was more effective than Ramipril 2.5 mg OD in controlling the SBP and improving Insulin resistance at the end of 12 weeks.

Metrics

Metrics Loading ...

References

Salve PS, Khanwelkar CC, Salve PS, Thorat VM, Matule SM. Effects of angiotensin converting enzyme inhibitor: ramipril on different biochemical parameters in essential hypertensive patients. Int J Res Med Sci. 2017 Jan 2;4(6):2288-91.

Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report from the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, de Ferranti SD, et al. Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association. Circulation. 2017;135(10):e146-e603.

Beale EG. Insulin Signaling and Insulin Resistance. J Investig Med Off Publ Am Fed Clin Res. 2013 Jan;61(1):11-4.

Manrique C, Lastra G, Gardner M, Sowers JR. The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Med Clin North Am. 2009 May;93(3):569-82.

Wilcox G. Insulin and Insulin Resistance. Clin Biochem Rev. 2005 May;26(2):19-39.

Plavnik FL, Ribeiro AB. A multicenter, open-label study of the efficacy and safety of telmisartan in mild to moderate hypertensive patients. Arq Bras Cardiol. 2002 Oct;79(4):339-50.

Lacourcière Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006 Jan;19(1):104-12.

Tripathy JP, Thakur JS, Jeet G, Chawla S, Jain S. Alarmingly high prevalence of hypertension and pre-hypertension in North India-results from a large cross-sectional STEPS survey. PLoS ONE [Internet]. 2017 Dec 21;12(12):e0188619.

Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005 Mar;28(3):757-8.

Podila KS, Pathapati R, Sreebhushanraju, Vijayalakshmi K, Ramesh V. A Comparative Study to Evaluate the Effect of Ramipril and Telmisartan on the Components of Metabolic Syndrome in Chronic Kidney Disease Patients. Int J Pharm and Biological Sci. 2014 Apr-June;4(2):122-7.

de Luis DA, Conde R, González-Sagrado M, Aller R, Izaola O, Dueñas A, et al. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp. 2010 Apr;25(2):275-9.

Rivara MB, Mehrotra R. New-Onset Diabetes in Peritoneal Dialysis Patients - Which Predictors Really Matter? Perit Dial Int J Int Soc Perit Dial. 2016;36(3):243-6.